United Therapeutics (UTHR) CEO A Sells $4.7M of Stock
Key Points
- United Therapeutics Corporation Chairperson and CEO Martine Rothblatt sold 9,500 shares on September 17, 2026, in a planned transaction valued at roughly $4.7 million.
- Major institutional investors adjusted their holdings earlier in the year, with Avoro Capital Advisors LLC increasing its stake to 2.8 million shares.
- The specialty pharmaceutical company trades above its 50-day and 200-day moving averages as it approaches its next quarterly financial report.
Since the trade, $UTHR is down 5.0% after 1 week, up 8.7% after 1 month and up 8.7% to date (from the $497.27 close on Sep 17, 2026).
Get United Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $UTHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
United Therapeutics Corporation Chairperson and CEO Martine Rothblatt sold 9,500 shares of stock on September 17, 2026, for a total value of about $4.7 million. According to a Form 4 filing with the Securities and Exchange Commission, the transaction took place at an average price of $496.06 per share under a pre-arranged Rule 10b5-1 trading plan. On the day of the trade, the stock closed at $497.27. Later, on October 9, October 12, October 13, and October 14, Rothblatt executed additional planned sales of 9,500 shares each.
UTHR
United Therapeutics Corporation
Inside Rothblatt's United Therapeutics Trade
Rothblatt disposed of 9,500 shares in the mid-September transaction, generating approximately $4.71 million. The sale was executed pursuant to a pre-arranged trading plan adopted by the company leader. Following the trade, Rothblatt retained a substantial ownership stake in the specialty drug developer.
Other Institutional Activity in United Therapeutics
Other large institutional investors made notable adjustments to their portfolios earlier in the year. Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1.48 billion. Renaissance Technologies, LLC reduced its position by 78,271 shares, finishing with 1,708,739 shares valued at roughly $911.0 million. Meanwhile, Jupiter Topco LLC doubled its stake by adding 415,564 shares for a total of 831,129 shares valued at about $443.1 million.
United Therapeutics Corporation Stock Up 0.1%
Shares recently traded around $541.98, sitting up about 9.0% from their close on the day of the CEO's September trade. The stock holds above both its 50-day moving average of $514.66 and its 200-day moving average of $526.82.
Recent Earnings
United Therapeutics reported trailing-twelve-month revenue of $3.15 billion alongside earnings of $27.92 per share. The healthcare firm is scheduled to release its next financial results on October 28, 2026.
Dividend
The company maintains a dividend payout ratio of 0.0% and offers no dividend yield.
Insider Buying and Selling at United Therapeutics Corporation
Insiders executed additional planned sales following the September transaction, including multiple disposals by CEO Martine Rothblatt in October.
Analysts Set New Price Targets
Wall Street firms have issued varied perspectives on the drug maker, with Goldman Sachs initiating coverage in late September with a Sell rating and a $321 price target.
About United Therapeutics
United Therapeutics Corporation focuses on creating and commercializing treatments for patients dealing with severe and chronic medical conditions. The Silver Spring, Maryland-based specialty pharmaceutical firm works primarily on rare diseases and advanced therapies.
Bottom Line
Investors will look toward the company's upcoming earnings release on October 28, 2026, for further updates on financial performance and product pipeline progress.
Related Filing Alerts
Source: Rothblatt Martine A's Form 4 filing on $UTHR (Sep 17, 2026). Written by software, not financial advice. How we make alerts